Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial
Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial have?
Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial has 60 citations in the OpenAlex counts ScholarIQ stores.
When was Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial published?
Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial has 2022 year in the ScholarIQ index.
What is the open-access status of Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial?
Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial has green oa status in the ScholarIQ index.
What is the DOI of Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial?
The DOI for Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial is on the source record.
What is the PMID of Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial?
The PMID for Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial is on the source record.
What is the OpenAlex record for Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial?
The OpenAlex for Efficacy of Combined <i>Abelmoschus manihot</i> and Irbesartan for Reduction of Albuminuria in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Multicenter Randomized Double-Blind Parallel Controlled Clinical Trial is on the source record.